Lyell Immunopharma, Inc.
Ticker: 1806952
P/L Snapshot
Q3 FY26 · consolidated
vs Q2 FY26·vs Q3 FY25
Revenue
0.00
-100.0%
Expenditure
48.30
+2.0%+29.6%
Net Profit
-45.53
-1.7%-17.2%
OPM %
-100.00%
Shareholding
Pattern breakdown
P/L Trends
(in millions)
RevenueExpenditureNet Profit
Price Chart
Latest News
Corporate Events
Board MeetingLYEL
202610Jun
Board Meeting
2026 Annual Meeting of Stockholders to elect Class II direct…
SEC Filing ↗